Orasis Pharmaceuticals announced it has closed a $13 million Series B financing, according to a press release.
Led by Visionary Ventures, with participation from Sequoia Capital, SBI (Japan) Innovation Ventures, LifeSci Venture Partners and private investors, the funding will go toward advancing the company’s product candidate, CSF-1, through completion of a phase 2b clinical trial, the release said. CSF-1 is an eye drop under development for presbyopia symptoms.
The financing will also be used for preparation of a phase 3 trial and precommercial activities.
“The recent Series B
Uncategorized